Pfizer's Earnings Made Easy

Mid-summer is considered prime beach season, but investors know more importantly -- it is second-quarter earnings season.

With that in mind, this episode of The Motley Fool's Market Checkup is dedicated to heavy hitters in the pharmaceutical industry. Watch and find out how the second-quarter results of four big pharma stocks stack up, and what challenges and opportunities lie ahead for them.

In this video, health-care analysts David Williamson and Max Macaluso drill down on Pfizer's recent results, detailing everything investors need to know, including what the dramatic reorganization means for the company's future.

Rising health-care costs continue to be a hotly debated topic, and even legendary investor Warren Buffett called this trend "the tapeworm that's eating at American competitiveness." To learn more about what's happening to the health-care system -- and how to potentially profit from this trend -- click here for free, immediate access.

Follow David on Twitter: @MotleyDavid.

The article Pfizer's Earnings Made Easy originally appeared on Fool.com.

David Williamson owns shares of Pfizer and Zoetis. Follow David on Twitter: @MotleyDavid. Max Macaluso, Ph.D. has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.